Clinical trial

Patient-reported Outcomes in Vericiguat-treated Patients With HFpEF

NCT03547583

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2018-06-15

PhasePHASE2

Study timeline

Study start (actual)2018-06-15Date precision: day

Registry last updated2021-01-06

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Chronic Heart Failure With Preserved Ejection Fractionunresolved

Interventions

Vericiguat (BAY1021189) 2.5 mg, 5 mg or 10 mg IR tabletsDRUG

PlaceboDRUG

Sponsors & collaborators

Bayerlead sponsor

Merck Sharp & Dohme LLCcollaborator

Canadian VIGOUR Centrecollaborator

Duke Clinical Research Institutecollaborator

Mapped research locations

TaipeiTaiwan3 BudapestHungary3 ViennaAustria3 SofiaBulgaria3 MontrealQuebec, Canada2 MoscowRussia2 Saint PetersburgRussia2 SingaporeSingapore2 WroclawPoland2 LisbonPortugal2 ThessalonikiGreece2 MilanLombardy, Italy2

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03547583 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.